

FOR OFFICIAL USE ONLY

ACCESS DB # 307584
PLEASE PRINT CLEARLY

RECEIVED

Scientific and Technical Information Center

SEP-3 2009

SEARCH REQUEST FORM

SCIENTIFIC DIVISION

Requester (SPM) Name: JAMES D. ANDERSON Examiner # _____ Date: 9/3/09
 Art Unit: 1614 Phone Number: 2-9038 Serial Number: 10/594,412
 Location (Bldg/Room): Room 1074 (Mailbox #: Room 3074) Results Format Preferred (circle): PAPER DISK

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following! M9

Title of Invention: USE OF 9H-2,6-DIAMINE DERIVATIVES

Inventors (please provide full names): BAENTELI, ROLF ; CHENE, PATRICK ; COLLINGWOOD,
STEPHEN ; FURET, PASCAL ; MEIER, PETER ; SCHOEPFER, JOSEPH

Earliest Priority Date: 4/5/2004

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the exact species or structures, descriptors, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only Please include all pertinent information (parent, child, divisional, or related parent numbers) along with the appropriate serial number.

① PLEASE SEARCH COMPOUNDS OF THE ATTACHED
 FORMULA (I) IN CLAIM 4.

THANKS!

JDM

RECEIVED
 SEP-3 2009
 SCIENTIFIC DIVISION


INVENTOR SEARCH

=> d ibib abs hitstr 19 1

L9 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on STN
 ACCESSION NUMBER: 2005:1123774 HCAPLUS Full-text
 DOCUMENT NUMBER: 143:405752
 TITLE: Preparation and use of 9H-purine-2,6-diamine derivatives in the treatment of cancer
 INVENTOR(S): Baenteli, Rolf; Chene, Patrick; Collingwood, Stephen Paul; Furet, Pascal; Meier, Peter; Schoepfer, Joseph
 PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
 SOURCE: PCT Int. Appl., 70 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.				KIND		DATE		APPLICATION NO.								DATE																																																																																					
-----				----		-----		-----								-----																																																																																					
WO 2005097135				A2		20051020		WO 2005-EP3521								20050404																																																																																					
WO 2005097135				A3		20060216																																																																																															
W:				AE,	AG,	AL,	AM,	AT,	AU,	AZ,	BA,	BB,	BG,	BR,	BW,	BY,	BZ,	CA,	CH,	CN,	CO,	CR,	CU,	CZ,	DE,	DK,	DM,	DZ,	EC,	EE,	EG,	ES,	FI,	GB,	GD,	GE,	GH,	GM,	HR,	HU,	ID,	IL,	IN,	IS,	JP,	KE,	KG,	KM,	KP,	KR,	KZ,	LC,	LK,	LR,	LS,	LT,	LU,	LV,	MA,	MD,	MG,	MK,	MN,	MW,	MX,	MZ,	NA,	NI,	NO,	NZ,	OM,	PG,	PH,	PL,	PT,	RO,	RU,	SC,	SD,	SE,	SG,	SK,	SL,	SM,	SY,	TJ,	TM,	TN,	TR,	TT,	TZ,	UA,	UG,	US,	UZ,	VC,	VN,	YU,	ZA,	ZM,	ZW
RW:				BW,	GH,	GM,	KE,	LS,	MW,	MZ,	NA,	SD,	SL,	SZ,	TZ,	UG,	ZM,	ZW,	AM,	AZ,	BY,	KG,	KZ,	MD,	RU,	TJ,	TM,	AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	IE,	IS,	IT,	LT,	LU,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR,	BF,	BJ,	CF,	CG,	CI,	CM,	GA,	GN,	GQ,	GW,	ML,	MR,	NE,	SN,	TD,	TG																													
AU 2005230388				A1		20051020		AU 2005-230388								20050404																																																																																					
CA 2559014				A1		20051020		CA 2005-2559014								20050404																																																																																					
EP 1734968				A2		20061227		EP 2005-751682								20050404																																																																																					
R:				AT,	BE,	BG,	CH,	CY,	CZ,	DE,	DK,	EE,	ES,	FI,	FR,	GB,	GR,	HU,	IE,	IS,	IT,	LI,	LT,	LU,	MC,	NL,	PL,	PT,	RO,	SE,	SI,	SK,	TR																																																																				
CN 1946405				A		20070411		CN 2005-80012119								20050404																																																																																					
BR 2005009655				A		20071009		BR 2005-9655								20050404																																																																																					
JP 2007531721				T		20071108		JP 2007-505519								20050404																																																																																					
MX 2006011486				A		20070312		MX 2006-11486								20061004																																																																																					
KR 2007033962				A		20070327		KR 2006-720763								20061004																																																																																					
IN 2006CN03675				A		20070706		IN 2006-CN3675								20061005																																																																																					
US 20070249639				A1		20071025		US 2007-594412								20070530																																																																																					
PRIORITY APPLN. INFO.:								GB 2004-7723								A 20040405																																																																																					
								WO 2005-EP3521								W 20050404																																																																																					
OTHER SOURCE(S):				CASREACT 143:405752; MARPAT 143:405752																																																																																																	
GI																																																																																																					



AB The title compds. I [R2 = aryl, bicyclic aryl, heteroaryl, bicyclic heteroaryl; R6 = aryl, heteroaryl, bicyclic aryl, bicyclic heteroaryl, aliphatic moiety; R8 = H, halo, lower alkyl, lower alkenyl, cycloalkyl, COMe, NR12R13, R12, R13 = H, lower alkyl; R9 = H, lower alkyl; NR6R9 = heterocycle] were prepared. For example, reacting 2-chloro-6-(cycloheptylamino)-9H-purine with 6-aminobenzothiazole gave I [R2 = benzothiazol-6-yl, R6 = cycloheptyl, R8 = R9 = H]. I are useful in treating proliferative diseases dependent on topoisomerase II.


IT ~~142805-56-9~~, Topoisomerase II

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of 9H-purine-2,6-diamine derivs., anticancer activity and


kinase inhibition)
 RN 142805-56-9 HCAPLUS
 CN Isomerase, deoxyribonucleate topo-, II (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


IT 867031-80-9P 867031-81-0P 867031-82-1P
 867031-83-2P 867031-84-3P 867031-85-4P
 867031-86-5P 867031-87-6P 867031-88-7P
 867031-89-8P 867031-90-1P 867031-91-2P
 867031-92-3P 867031-93-4P 867031-94-5P
 867031-95-6P 867031-96-7P 867031-98-9P
 867031-99-0P 867032-03-9P 867032-04-0P
 867032-05-1P 867032-07-3P 867032-08-4P,
 [6-[2-(Morpholin-4-yl)ethoxy]naphthalen-2-yl]amine 867032-09-5P
 , [2-[2-(Morpholin-4-yl)ethoxy]benzothiazol-6-yl]amine
 867032-10-8P, 4-[2-[(6-Bromonaphthalen-2-yl)oxy]ethyl]morpholine
 867032-11-9P, 2-Methyl-5-nitro-1H-indole-1-carboxylic acid
 tert-butyl ester 867032-13-1P,
 2-[2-(Morpholin-4-yl)ethoxy]-6-nitrobenzothiazole 867032-15-3P
 867032-18-6P, 9-[Bis(4-methoxyphenyl)methyl]-2,6-dichloro-9H-
 purine 867032-20-0P 867032-25-5P
 867032-28-8P 867032-29-9P 867032-31-3P
 867032-32-4P 867032-33-5P 867032-34-6P
 867032-35-7P 867032-36-8P 867032-37-9P
 867032-38-0P 867032-39-1P 867032-40-4P
 867032-42-6P 867032-43-7P 867032-44-8P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
 preparation); THU (Therapeutic use); BIOL (Biological study); PREP
 (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of 9H-purine-2,6-diamine derivs., anticancer activity and
 kinase inhibition)
 RN 867031-80-9 HCAPLUS
 CN 9H-Purin-6-amine, 2-chloro-N-cycloheptyl- (CA INDEX NAME)



RN 867031-81-0 HCAPLUS
 CN 1-Propanol, 2-[(2-chloro-9H-purin-6-yl)amino]-2-methyl- (CA INDEX NAME)




RN 867031-82-1 HCAPLUS

CN 9H-Purin-6-amine, 2-chloro-N-tricyclo[3.3.1.1^{3,7}]dec-2-yl- (CA INDEX NAME)


RN 867031-83-2 HCAPLUS

CN 9H-Purin-6-amine, 2-chloro-N-cyclooctyl- (CA INDEX NAME)




RN 867031-84-3 HCAPLUS

CN Cyclohexanol, 4-[(2-chloro-9H-purin-6-yl)amino]- (CA INDEX NAME)




RN 867031-85-4 HCAPLUS

CN 6-Quinolinamine, N-(2-chloro-9H-purin-6-yl)- (CA INDEX NAME)




RN 867031-86-5 HCAPLUS

CN 9H-Purin-6-amine, 2-chloro-N-(diphenylmethyl)- (CA INDEX NAME)




RN 867031-87-6 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(diphenylmethyl)-N2-6-quinolinyl-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867031-88-7 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(1,1-dimethylethyl)-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867031-89-8 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-2-naphthalenyl-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867031-90-1 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-(2-methyl-6-quinolinyl)-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867031-91-2 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-(2-methyl-5-benzothiazolyl)-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867031-92-3 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-[2-(1,1-dimethylethyl)-6-benzothiazolyl]-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867031-93-4 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-cycloheptyl-N2-6-quinolinyl-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867031-94-5 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-[4-(2-benzothiazolyl)phenyl]-N6-(1,1-dimethylethyl)-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867031-95-6 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-(6-methoxy-2-naphthalenyl)-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)



RN 867031-96-7 HCAPLUS


CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-[6-[2-(4-morpholinyl)ethoxy]-2-naphthalenyl]-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)



RN 867031-98-9 HCAPLUS

CN 9H-Purine-2,6-diamine, 9-[bis(4-methoxyphenyl)methyl]-N6-(1,1-dimethylethyl)-8-ethyl-N2-[2-[2-(4-morpholinyl)ethoxy]-6-benzothiazolyl]-(CA INDEX NAME)

PAGE 1-A




PAGE 1-B

—OMe


RN 867031-99-0 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-ethyl-N2-[2-[2-(4-morpholinyl)ethoxy]-6-benzothiazolyl]-9-(tetrahydro-2H-pyran-2-yl)-(CA INDEX NAME)




RN 867032-03-9 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-8-cyclopropyl-N6-(1,1-dimethylethyl)-9-(tetrahydro-2H-pyran-2-yl)-(CA INDEX NAME)




RN 867032-04-0 HCAPLUS

CN 9H-Purine-2,6,8-triamine, N2-6-benzothiazolyl-N8-[(2,4-dimethoxyphenyl)methyl]-N6-(1,1-dimethylethyl)-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867032-05-1 HCAPLUS

CN 9H-Purine-2,6,8-triamine, N8-[(2,4-dimethoxyphenyl)methyl]-N6-(1,1-dimethylethyl)-N2-2-naphthalenyl-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867032-07-3 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(1,1-dimethylethyl)-8-(1-ethoxyethenyl)-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867032-08-4 HCAPLUS

CN 2-Naphthalenamine, 6-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 867032-09-5 HCAPLUS

CN 6-Benzothiazolamine, 2-[2-(4-morpholinyl)ethoxy]- (CA INDEX NAME)




RN 867032-10-8 HCAPLUS

CN Morpholine, 4-[2-[(6-bromo-2-naphthalenyl)oxy]ethyl]- (CA INDEX NAME)




RN 867032-11-9 HCAPLUS

CN 1H-Indole-1-carboxylic acid, 2-methyl-5-nitro-, 1,1-dimethylethyl ester
(CA INDEX NAME)



RN 867032-13-1 HCAPLUS


CN Benzothiazole, 2-[2-(4-morpholinyl)ethoxy]-6-nitro- (CA INDEX NAME)



RN 867032-15-3 HCAPLUS


CN 9H-Purin-6-amine, 2-chloro-N-(1,1-dimethylethyl)-9-(tetrahydro-2H-pyran-2-

yl)- (CA INDEX NAME)




RN 867032-18-6 HCAPLUS

CN 9H-Purine, 9-[bis(4-methoxyphenyl)methyl]-2,6-dichloro- (CA INDEX NAME)




RN 867032-20-0 HCAPLUS

CN 9H-Purin-6-amine, 2-chloro-N-(1,1-dimethylethyl)-8-ethyl- (CA INDEX NAME)




RN 867032-25-5 HCAPLUS

CN 9H-Purin-6-amine, 8-bromo-2-chloro-N-(1,1-dimethylethyl)-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867032-28-8 HCAPLUS

CN 9H-Purine, 8-bromo-2,6-dichloro-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867032-29-9 HCAPLUS

CN 9H-Purine, 2,6-dichloro-8-(1-ethoxyethenyl)-9-(tetrahydro-2H-pyran-2-yl)-
(CA INDEX NAME)




RN 867032-31-3 HCAPLUS

CN 9H-Purin-6-amine, 2-chloro-N-(1,1-dimethylethyl)-8-methyl- (CA INDEX
NAME)




RN 867032-32-4 HCAPLUS

CN 9H-Purin-6-amine, 2-chloro-N-cycloheptyl-8-methyl- (CA INDEX NAME)




RN 867032-33-5 HCAPLUS

CN 9H-Purin-6-amine, 2-chloro-8-ethyl-N-(2,2,2-trifluoro-1-methylethyl)- (CA
INDEX NAME)




RN 867032-34-6 HCAPLUS

CN 9H-Purine, 2-chloro-8-ethyl-6-(2-methyl-1-pyrrolidinyl)- (CA INDEX NAME)




RN 867032-35-7 HCAPLUS

CN Butanamide, 3-[(2-chloro-8-ethyl-9H-purin-6-yl)amino]- (CA INDEX NAME)




RN 867032-36-8 HCAPLUS

CN Butanoic acid, 3-[(2-chloro-8-ethyl-9H-purin-6-yl)amino]-, ethyl ester
(CA INDEX NAME)




RN 867032-37-9 HCAPLUS

CN 9H-Purin-6-amine, 2-chloro-N-(1,1-dimethylethyl)-8-propyl- (CA INDEX NAME)




RN 867032-38-0 HCAPLUS

CN 9H-Purin-6-amine, 2-chloro-N-(1,1-dimethylethyl)-8-(1-methylethyl)- (CA INDEX NAME)




RN 867032-39-1 HCAPLUS

CN 9H-Purin-6-amine, 2-chloro-8-cyclopentyl-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 867032-40-4 HCAPLUS

CN 9H-Purin-6-amine, 2-chloro-8-cyclopropyl-N-(1,1-dimethylethyl)- (CA INDEX NAME)



RN 867032-42-6 HCAPLUS


CN Ethanimidic acid, N-(4-amino-2,6-dichloro-5-pyrimidinyl)-, ethyl ester (CA INDEX NAME)




RN 867032-43-7 HCAPLUS

CN Propanimidic acid, N-(4-amino-2,6-dichloro-5-pyrimidinyl)-, ethyl ester

(CA INDEX NAME)



RN 867032-44-8 HCAPLUS


CN Butanimidic acid, N-(4-amino-2,6-dichloro-5-pyrimidinyl)-, methyl ester
(CA INDEX NAME)

IT	325166-80-1P	867032-49-3P	867032-50-6P
	867032-51-7P	867032-52-8P	867032-53-9P
	867032-54-0P	867032-55-1P	867032-56-2P
	867032-57-3P	867032-58-4P	867032-59-5P
	867032-60-8P	867032-61-9P	867032-62-0P
	867032-63-1P	867032-64-2P	867032-65-3P
	867032-66-4P	867032-67-5P	867032-68-6P
	867032-69-7P	867032-70-0P	867032-71-1P
	867032-72-2P	867032-73-3P	867032-74-4P
	867032-75-5P	867032-76-6P	867032-77-7P
	867032-78-8P	867032-79-9P	867032-80-2P
	867032-81-3P	867032-82-4P	867032-83-5P
	867032-84-6P	867032-85-7P	867032-86-8P
	867032-87-9P	867032-88-0P	867032-89-1P
	867032-90-4P	867032-91-5P	867032-92-6P
	867032-93-7P	867032-94-8P	867032-95-9P
	867032-96-0P	867032-97-1P	867032-98-2P
	867032-99-3P	867033-00-9P	867033-01-0P
	867033-02-1P	867033-03-2P	867033-04-3P
	867033-05-4P	867033-06-5P	867033-07-6P
	867033-08-7P	867033-09-8P	867033-10-1P
	867033-11-2P	867033-12-3P	867033-13-4P
	867033-14-5P	867033-15-6P	867033-16-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL
(Biological study); PREP (Preparation)(preparation of 9H-purine-2,6-diamine derivs., anticancer activity and
kinase inhibition)


RN 325166-80-1 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(1,1-dimethylethyl)- (CA
INDEX NAME)




RN 867032-49-3 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-cycloheptyl- (CA INDEX NAME)




RN 867032-50-6 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-cycloheptyl-N2-[4-(2-thiazolyl)phenyl]- (CA INDEX NAME)




RN 867032-51-7 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-cycloheptyl-N2-6-quinolinyl- (CA INDEX NAME)




RN 867032-52-8 HCAPLUS

CN 1-Propanol, 2-[[2-(6-benzothiazolylamino)-9H-purin-6-yl]amino]-2-methyl- (CA INDEX NAME)




RN 867032-53-9 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-tricyclo[3.3.1.1^{3,7}]dec-2-yl-
(CA INDEX NAME)




RN 867032-54-0 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-bicyclo[2.2.1]hept-2-yl-
(CA INDEX NAME)



RN 867032-55-1 HCAPLUS


CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-cyclooctyl- (CA INDEX NAME)



RN 867032-56-2 HCAPLUS


CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(3-methoxyphenyl)- (CA

INDEX NAME)




RN 867032-57-3 HCAPLUS

CN Cyclohexanol, 4-[[2-(6-benzothiazolylamino)-9H-purin-6-yl]amino]- (CA INDEX NAME)




RN 867032-58-4 HCAPLUS

CN 9H-Purine-2,6-diamine, N2,N6-di-6-quinolinyl- (CA INDEX NAME)




RN 867032-59-5 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(diphenylmethyl)- (CA INDEX NAME)




RN 867032-60-8 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-phenyl-N2-6-quinolinyl- (CA INDEX NAME)




RN 867032-61-9 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(diphenylmethyl)-N2-6-quinolinyl- (CA INDEX NAME)




RN 867032-62-0 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-2-naphthalenyl- (CA INDEX NAME)




RN 867032-63-1 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-(2-methyl-6-quinolinyl)- (CA INDEX NAME)




RN 867032-64-2 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-(2-methyl-5-benzothiazolyl)- (CA INDEX NAME)




RN 867032-65-3 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-[2-(1,1-dimethylethyl)-6-benzothiazolyl]- (CA INDEX NAME)




RN 867032-66-4 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-(2-methyl-6-benzothiazolyl)- (CA INDEX NAME)




RN 867032-67-5 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-[4-(2-benzothiazolyl)phenyl]-N6-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 867032-68-6 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-(6-methoxy-2-naphthalenyl)- (CA INDEX NAME)




RN 867032-69-7 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-[6-[2-(4-morpholinyl)ethoxy]-2-naphthalenyl]- (CA INDEX NAME)




RN 867032-70-0 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-(2-methyl-1H-indol-5-yl)-
(CA INDEX NAME)




RN 867032-71-1 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-1H-indol-5-yl- (CA INDEX NAME)




RN 867032-72-2 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(1,1-dimethylethyl)-8-methyl-
(CA INDEX NAME)




RN 867032-73-3 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-cycloheptyl-8-methyl- (CA INDEX NAME)




RN 867032-74-4 HCAPLUS


CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(1,1-dimethylethyl)-8-ethyl-
(CA INDEX NAME)

RN 867032-75-5 HCAPLUS


CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-8-ethyl-N6-(2,2,2-trifluoro-1-methylethyl)- (CA INDEX NAME)



RN 867032-76-6 HCAPLUS


CN 9H-Purin-2-amine, N-6-benzothiazolyl-8-ethyl-6-(2-methyl-1-pyrrolidinyl)-
(CA INDEX NAME)

RN 867032-77-7 HCAPLUS

CN Butanamide, 3-[[2-(6-benzothiazolylamino)-8-ethyl-9H-purin-6-yl]amino]-
(CA INDEX NAME)


RN 867032-78-8 HCAPLUS

CN Butanoic acid, 3-[[2-(6-benzothiazolylamino)-8-ethyl-9H-purin-6-yl]amino]-
, ethyl ester (CA INDEX NAME)




RN 867032-79-9 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(1,1-dimethylethyl)-8-propyl-
(CA INDEX NAME)




RN 867032-80-2 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(1,1-dimethylethyl)-8-(1-methylethyl)- (CA INDEX NAME)




RN 867032-81-3 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-8-cyclopentyl-N6-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 867032-82-4 HCAPLUS

CN 2H-1-Benzopyran-2-one, 6-[[[6-[(1,1-dimethylethyl)amino]-8-ethyl-9H-purin-2-yl]amino]- (CA INDEX NAME)




RN 867032-83-5 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-ethyl-N2-[2-(methylthio)-6-benzothiazolyl]- (CA INDEX NAME)




RN 867032-84-6 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-ethyl-N2-[2-[2-(4-morpholinyl)ethoxy]-6-benzothiazolyl]- (CA INDEX NAME)




RN 867032-85-7 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-(1-methylethyl)-N2-[2-[2-(4-morpholinyl)ethoxy]-6-benzothiazolyl]- (CA INDEX NAME)




RN 867032-86-8 HCAPLUS

CN 9H-Purine-2,6-diamine, 8-cyclopropyl-N6-(1,1-dimethylethyl)-N2-[2-[2-(4-morpholinyl)ethoxy]-6-benzothiazolyl]- (CA INDEX NAME)




RN 867032-87-9 HCAPLUS

CN 9H-Purine-2,6-diamine, 8-cyclopentyl-N6-(1,1-dimethylethyl)-N2-[2-[2-(4-morpholinyl)ethoxy]-6-benzothiazolyl]- (CA INDEX NAME)




RN 867032-88-0 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-8-cyclopropyl-N6-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 867032-89-1 HCAPLUS

CN 9H-Purine-2,6,8-triamine, N2-6-benzothiazolyl-N6-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 867032-90-4 HCAPLUS

CN 9H-Purine-2,6,8-triamine, N6-(1,1-dimethylethyl)-N2-2-naphthalenyl- (CA INDEX NAME)




RN 867032-91-5 HCAPLUS

CN 9H-Purine-2,6,8-triamine, N6-(1,1-dimethylethyl)-N8-methyl-N2-2-naphthalenyl- (CA INDEX NAME)




RN 867032-92-6 HCAPLUS

CN Ethanone, 1-[2-(6-benzothiazolylamino)-6-[(1,1-dimethylethyl)amino]-9H-purin-8-yl]- (CA INDEX NAME)




RN 867032-93-7 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-6-quinolinyl- (CA INDEX NAME)




RN 867032-94-8 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-2,1,3-benzothiadiazol-5-yl-N6-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 867032-95-9 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-2,1,3-benzothiadiazol-5-yl-N6-cycloheptyl- (CA INDEX NAME)




RN 867032-96-0 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-cycloheptyl-N2-(2-methyl-6-benzothiazolyl)- (CA INDEX NAME)




RN 867032-97-1 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(1,1-dimethylpropyl)- (CA INDEX NAME)




RN 867032-98-2 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylpropyl)-N2-6-quinolinyl- (CA INDEX NAME)




RN 867032-99-3 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-2,1,3-benzothiadiazol-5-yl-N6-(1,1-dimethylpropyl)- (CA INDEX NAME)




RN 867033-00-9 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylpropyl)-N2-(2-methyl-6-benzothiazolyl)- (CA INDEX NAME)




RN 867033-01-0 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-[2-(4-fluorophenyl)-1,1-dimethylethyl]- (CA INDEX NAME)




RN 867033-02-1 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-[2-(4-fluorophenyl)-1,1-dimethylethyl]-N2-6-quinolinyl- (CA INDEX NAME)




RN 867033-03-2 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-2,1,3-benzothiadiazol-5-yl-N6-[2-(4-fluorophenyl)-1,1-dimethylethyl]- (CA INDEX NAME)




RN 867033-04-3 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-[2-(4-fluorophenyl)-1,1-dimethylethyl]-N2-(2-methyl-6-benzothiazolyl)- (CA INDEX NAME)




RN 867033-05-4 HCAPLUS

CN 9H-Purine-2-amine, N6-benzothiazolyl-6-[4-(3-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 867033-06-5 HCAPLUS

CN 9H-Purine-2-amine, N6-benzothiazolyl-6-[4-(2-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 867033-07-6 HCAPLUS

CN 6-Quinolinamine, N-[6-[4-(2-pyridinyl)-1-piperazinyl]-9H-purin-2-yl]- (CA INDEX NAME)




RN 867033-08-7 HCAPLUS

CN 9H-Purin-2-amine, N-2,1,3-benzothiadiazol-5-yl-6-[4-(2-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 867033-09-8 HCAPLUS

CN 9H-Purin-2-amine, N-(2-methyl-6-benzothiazolyl)-6-[4-(2-pyridinyl)-1-piperazinyl]- (CA INDEX NAME)




RN 867033-10-1 HCAPLUS

CN 6-Quinolinamine, N-[6-[4-(2-pyrazinyl)-1-piperazinyl]-9H-purin-2-yl]- (CA INDEX NAME)




RN 867033-11-2 HCAPLUS

CN 9H-Purine-2,6-diamine, 8-bromo-N6-(1,1-dimethylethyl)-N2-2-naphthalenyl- (CA INDEX NAME)




RN 867033-12-3 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-ethenyl-N2-2-naphthalenyl- (CA INDEX NAME)




RN 867033-13-4 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-2-naphthalenyl-8-(2-propen-1-yl)- (CA INDEX NAME)




RN 867033-14-5 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-methyl-N2-2-naphthalenyl-
(CA INDEX NAME)




RN 867033-15-6 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-ethyl-N2-2-naphthalenyl-
(CA INDEX NAME)



RN 867033-16-7 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-(2-methylpropyl)-N2-2-naphthalenyl-
(CA INDEX NAME)



IT 867032-12-0P, 5-Amino-2-methylindole-1-carboxylic acid
tert-butyl ester 867032-14-2P 867032-16-4P

867032-17-5P 867032-19-7P 867032-21-1P

867032-22-2P 867032-23-3P 867032-24-4P

867032-26-6P 867032-27-7P 867032-30-2P

867033-17-8P 867033-18-9P 867033-19-0P

867033-20-3P 867033-21-4P 867033-22-5P


867033-23-6P 867033-24-7P 867033-25-8P

867033-27-0P 867033-28-1P 867033-29-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation of 9H-purine-2,6-diamine derivs., anticancer activity and
kinase inhibition)


RN 867032-12-0 HCAPLUS

CN 1H-Indole-1-carboxylic acid, 5-amino-2-methyl-, 1,1-dimethylethyl ester
(CA INDEX NAME)

RN 867032-14-2 HCAPLUS


CN 9H-Purin-6-amine, 2-chloro-N-(diphenylmethyl)-9-(tetrahydro-2H-pyran-2-yl)-
(CA INDEX NAME)

RN 867032-16-4 HCAPLUS

CN 9H-Purin-6-amine, 2-chloro-N-cycloheptyl-9-(tetrahydro-2H-pyran-2-yl)-
(CA INDEX NAME)


RN 867032-17-5 HCAPLUS

CN 9H-Purin-6-amine, 2-chloro-8-cyclopropyl-N-(1,1-dimethylethyl)-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867032-19-7 HCAPLUS

CN 9H-Purin-6-amine, 9-[bis(4-methoxyphenyl)methyl]-2-chloro-N-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 867032-21-1 HCAPLUS

CN 9H-Purin-6-amine, 9-[bis(4-methoxyphenyl)methyl]-2-chloro-N-(1,1-dimethylethyl)-8-ethyl- (CA INDEX NAME)




RN 867032-22-2 HCAPLUS

CN 9H-Purin-6-amine, 2-chloro-N-(1,1-dimethylethyl)-8-ethyl-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867032-23-3 HCAPLUS

CN 9H-Purin-6-amine, 2-chloro-8-cyclopentyl-N-(1,1-dimethylethyl)-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867032-24-4 HCAPLUS

CN 9H-Purin-6-amine, 2-chloro-8-cyclopentyl-N-(1,1-dimethylethyl)-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867032-26-6 HCAPLUS

CN 9H-Purine-6,8-diamine, 2-chloro-N8-[(2,4-dimethoxyphenyl)methyl]-N6-(1,1-dimethylethyl)-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867032-27-7 HCAPLUS

CN 9H-Purine-6,8-diamine, 2-chloro-N8-[(2,4-dimethoxyphenyl)methyl]-N6-(1,1-dimethylethyl)-N8-methyl-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867032-30-2 HCAPLUS

CN 9H-Purin-6-amine, 2-chloro-N-(1,1-dimethylethyl)-8-(1-ethoxyethenyl)-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867033-17-8 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-cycloheptyl-8-ethyl- (CA INDEX NAME)




RN 867033-18-9 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-(1-methylethyl)-N2-[3-[5-methyl-2-[2-(4-morpholinyl)ethoxy]-4-thiazolyl]-2-propen-1-ylidene]- (CA INDEX NAME)




RN 867033-19-0 HCAPLUS

CN 9H-Purine-2,6-diamine, 8-cyclopropyl-N6-(1,1-dimethylethyl)-N2-[3-[5-methyl-2-[2-(4-morpholinyl)ethoxy]-4-thiazolyl]-2-propen-1-ylidene]- (CA INDEX NAME)







RN 867033-20-3 HCAPLUS

CN 9H-Purine-2,6-diamine, 8-cyclopentyl-N6-(1,1-dimethylethyl)-N2-[3-[5-methyl-2-[2-(4-morpholinyl)ethoxy]-4-thiazolyl]-2-propen-1-ylidene]- (CA INDEX NAME)




RN 867033-21-4 HCAPLUS

CN 1H-Indole-1-carboxylic acid, 5-[[9-[bis(4-methoxyphenyl)methyl]-6-[(1,1-dimethylethyl)amino]-9H-purin-2-yl]amino]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 867033-25-8 HCAPLUS

CN 9H-Purine-2,6-diamine, 8-cyclopentyl-N6-(1,1-dimethylethyl)-N2-[3-[5-methyl-2-[2-(4-morpholinyl)ethoxy]-4-thiazolyl]-2-propen-1-ylidene]-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867033-27-0 HCAPLUS

CN Propanimidic acid, N-(4-amino-2,6-dichloro-5-pyrimidinyl)-2-methyl-, ethyl ester (CA INDEX NAME)




RN 867033-28-1 HCAPLUS

CN Cyclopentanecarboximidic acid, N-(4-amino-2,6-dichloro-5-pyrimidinyl)-, ethyl ester (CA INDEX NAME)



RN 867033-29-2 HCAPLUS

CN Cyclopropanecarboximidic acid, N-(4-amino-2,6-dichloro-5-pyrimidinyl)-, ethyl ester (CA INDEX NAME)



IT 75-64-9, tert-Butylamine, reactions 78-39-7
 91-00-9 91-59-8, 2-Naphthalenamine 110-87-2
 , 3,4-Dihydro-2H-pyran 115-80-0 124-68-5
 533-30-2, 6-Aminobenzothiazole 536-90-3


580-15-4, 6-Quinolinamine 594-39-8 597-64-8
 622-40-2, 2-(Morpholin-4-yl)ethanol 728-87-0,
 Bis(4-methoxyphenyl)methanol 765-38-8 822-98-0,
 Bicyclo[2.2.1]heptan-2-amine 874-37-3,
 2,1,3-Benzothiadiazol-5-amine 1089-59-4 1200-27-7
 2407-11-6, 2-Chloro-6-nitrobenzothiazole 2941-62-0
 3240-94-6, 4-(2-Chloroethyl)morpholine 3531-43-9
 5111-65-9, 2-Bromo-6-methoxynaphthalene 5303-65-1
 5451-40-1, 2,6-Dichloro-9H-purine 5452-35-7,
 Cycloheptylamine 5452-37-9, Cyclooctanamine
 5959-32-0 6278-73-5, 4-(2-Benzothiazolyl)benzenamine
 6850-65-3 7486-35-3 7570-47-0,
 2-Methyl-5-nitro-1H-indole 13074-39-0, 2-Adamantanamine
 13382-43-9, 2-Methylbenzothiazol-5-amine 14415-44-2
 15231-91-1, 6-Bromonaphthalen-2-ol 20419-68-5,
 2,6-Dichloro-9-(tetrahydropyran-2-yl)-9H-purine 20781-20-8,
 (2,4-Dimethoxybenzyl)amine 24850-33-7 25706-29-0
 34803-68-4 41796-01-4 43083-12-1
 58460-11-0, 2-(tert-Butyl)benzothiazol-6-amine
 65079-19-8, 2-Methyl-6-quinolinamine 67980-77-2
 97674-02-7, Tributyl(1-ethoxyvinyl)stannane 102503-23-1
 , (2,4-Dimethoxybenzyl)methylamine 130838-36-7
 166104-20-7, 1-(tert-Butoxycarbonyl)indol-5-amine
 185408-97-3 190654-89-8 193017-26-4
 411235-57-9, Cyclopropylboronic acid 736100-88-2
 746556-17-2 867032-48-2 1042953-23-0
 1042953-41-2 1042953-86-5

RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of 9H-purine-2,6-diamine derivs., anticancer activity and
 kinase inhibition)


RN 75-64-9 HCAPLUS

CN 2-Propanamine, 2-methyl- (CA INDEX NAME)




RN 78-39-7 HCAPLUS

CN Ethane, 1,1,1-triethoxy- (CA INDEX NAME)




RN 91-00-9 HCAPLUS

CN Benzenemethanamine, α -phenyl- (CA INDEX NAME)




RN 91-59-8 HCAPLUS
 CN 2-Naphthalenamine (CA INDEX NAME)




RN 110-87-2 HCAPLUS
 CN 2H-Pyran, 3,4-dihydro- (CA INDEX NAME)




RN 115-80-0 HCAPLUS
 CN Propane, 1,1,1-triethoxy- (CA INDEX NAME)




RN 124-68-5 HCAPLUS
 CN 1-Propanol, 2-amino-2-methyl- (CA INDEX NAME)




RN 533-30-2 HCAPLUS
 CN 6-Benzothiazolamine (CA INDEX NAME)




RN 536-90-3 HCAPLUS
 CN Benzenamine, 3-methoxy- (CA INDEX NAME)




RN 580-15-4 HCAPLUS
 CN 6-Quinolinamine (CA INDEX NAME)




RN 594-39-8 HCAPLUS
 CN 2-Butanamine, 2-methyl- (CA INDEX NAME)




RN 597-64-8 HCAPLUS
 CN Stannane, tetraethyl- (CA INDEX NAME)




RN 622-40-2 HCAPLUS
 CN 4-Morpholineethanol (CA INDEX NAME)




RN 728-87-0 HCAPLUS
 CN Benzenemethanol, 4-methoxy- α -(4-methoxyphenyl)- (CA INDEX NAME)




RN 765-38-8 HCAPLUS
 CN Pyrrolidine, 2-methyl- (CA INDEX NAME)




RN 822-98-0 HCAPLUS
 CN Bicyclo[2.2.1]heptan-2-amine (CA INDEX NAME)




RN 874-37-3 HCAPLUS
 CN 2,1,3-Benzothiadiazol-5-amine (CA INDEX NAME)




RN 1089-59-4 HCAPLUS
 CN Stannane, methyltriphenyl- (CA INDEX NAME)




RN 1200-27-7 HCAPLUS
 CN Benzeneethanamine, 4-fluoro- α,α -dimethyl- (CA INDEX NAME)




RN 2407-11-6 HCAPLUS
 CN Benzothiazole, 2-chloro-6-nitro- (CA INDEX NAME)




RN 2941-62-0 HCAPLUS
 CN 6-Benzothiazolamine, 2-methyl- (CA INDEX NAME)




RN 3240-94-6 HCAPLUS
 CN Morpholine, 4-(2-chloroethyl)- (CA INDEX NAME)




RN 3531-43-9 HCAPLUS
 CN Stannane, tetrakis(2-methylpropyl)- (CA INDEX NAME)



RN 5111-65-9 HCAPLUS
 CN Naphthalene, 2-bromo-6-methoxy- (CA INDEX NAME)




RN 5303-65-1 HCAPLUS
 CN Butanoic acid, 3-amino-, ethyl ester (CA INDEX NAME)




RN 5451-40-1 HCAPLUS

CN 9H-Purine, 2,6-dichloro- (CA INDEX NAME)




RN 5452-35-7 HCAPLUS

CN Cycloheptanamine (CA INDEX NAME)




RN 5452-37-9 HCAPLUS

CN Cyclooctanamine (CA INDEX NAME)




RN 5959-32-0 HCAPLUS

CN Butanamide, 3-amino- (CA INDEX NAME)




RN 6278-73-5 HCAPLUS

CN Benzenamine, 4-(2-benzothiazolyl)- (CA INDEX NAME)




RN 6850-65-3 HCAPLUS


CN Cyclohexanol, 4-amino- (CA INDEX NAME)




RN 7486-35-3 HCAPLUS
 CN Stannane, tributylethenyl- (CA INDEX NAME)




RN 7570-47-0 HCAPLUS
 CN 1H-Indole, 2-methyl-5-nitro- (CA INDEX NAME)




RN 13074-39-0 HCAPLUS
 CN Tricyclo[3.3.1.1^{3,7}]decan-2-amine (CA INDEX NAME)




RN 13382-43-9 HCAPLUS
 CN 5-Benzothiazolamine, 2-methyl- (CA INDEX NAME)



RN 14415-44-2 HCAPLUS
 CN 2H-1-Benzopyran-2-one, 6-amino- (CA INDEX NAME)




RN 15231-91-1 HCAPLUS
 CN 2-Naphthalenol, 6-bromo- (CA INDEX NAME)




RN 20419-68-5 HCAPLUS

CN 9H-Purine, 2,6-dichloro-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 20781-20-8 HCAPLUS

CN Benzenemethanamine, 2,4-dimethoxy- (CA INDEX NAME)




RN 24850-33-7 HCAPLUS

CN Stannane, tributyl-2-propen-1-yl- (CA INDEX NAME)




RN 25706-29-0 HCAPLUS

CN 6-Benzothiazolamine, 2-(methylthio)- (CA INDEX NAME)




RN 34803-68-4 HCAPLUS

CN Pyrazine, 2-(1-piperazinyl)- (CA INDEX NAME)




RN 41796-01-4 HCAPLUS


CN Propanimidic acid, 2-methyl-, methyl ester (CA INDEX NAME)




RN 43083-12-1 HCAPLUS
 CN Butane, 1,1,1-trimethoxy- (CA INDEX NAME)




RN 58460-11-0 HCAPLUS
 CN 6-Benzothiazolamine, 2-(1,1-dimethylethyl)- (CA INDEX NAME)




RN 65079-19-8 HCAPLUS
 CN 6-Quinolinamine, 2-methyl- (CA INDEX NAME)




RN 67980-77-2 HCAPLUS
 CN Piperazine, 1-(3-pyridinyl)- (CA INDEX NAME)



RN 97674-02-7 HCAPLUS
 CN Stannane, tributyl(1-ethoxyethenyl)- (CA INDEX NAME)




RN 102503-23-1 HCAPLUS
 CN Benzenemethanamine, 2,4-dimethoxy-N-methyl- (CA INDEX NAME)




RN 130838-36-7 HCAPLUS

CN 4,5-Pyrimidinediamine, 2,6-dichloro- (CA INDEX NAME)




RN 166104-20-7 HCAPLUS

CN 1H-Indole-1-carboxylic acid, 5-amino-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 185408-97-3 HCAPLUS

CN 9H-Purin-6-amine, 2-chloro-N-phenyl- (CA INDEX NAME)




RN 190654-89-8 HCAPLUS


CN 9H-Purin-6-amine, 2-chloro-N-(3-methoxyphenyl)- (CA INDEX NAME)




RN 193017-26-4 HCAPLUS
 CN Benzenamine, 4-(2-thiazolyl)- (CA INDEX NAME)




RN 411235-57-9 HCAPLUS
 CN Boronic acid, B-cyclopropyl- (CA INDEX NAME)




RN 736100-88-2 HCAPLUS
 CN Cyclopentanecarboximidic acid, methyl ester (CA INDEX NAME)



RN 746556-17-2 HCAPLUS
 CN Cyclopropanecarboximidic acid, methyl ester (CA INDEX NAME)




RN 867032-48-2 HCAPLUS
 CN 9H-Purin-6-amine, N-bicyclo[2.2.1]hept-2-yl-2-chloro- (CA INDEX NAME)




RN 1042953-23-0 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-(2-methyl-6-benzothiazolyl)-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 1042953-41-2 HCAPLUS

CN 1H-Indole-1-carboxylic acid, 5-[[6-[(1,1-dimethylethyl)amino]-1-(tetrahydro-2H-pyran-2-yl)-1H-purin-2-yl]amino]-2-methyl-, 1,1-dimethylethyl ester (CA INDEX NAME)



RN 1042953-86-5 HCAPLUS

CN 1H-Indole-1-carboxylic acid, 5-[[6-[(1,1-dimethylethyl)amino]-1-(tetrahydro-2H-pyran-2-yl)-1H-purin-2-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)



IT 13101-88-7P, 6-Methoxy-2-naphthalenamine 867031-97-8P

867032-00-6P 867032-01-7P 867032-02-8P

867032-45-9P 867032-46-0P 867032-47-1P


867033-26-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of 9H-purine-2,6-diamine derivs., anticancer activity and kinase inhibition)


RN 13101-88-7 HCAPLUS

CN 2-Naphthalenamine, 6-methoxy- (CA INDEX NAME)




RN 867031-97-8 HCAPLUS

CN 1H-Indole-1-carboxylic acid, 5-[[9-[bis(4-methoxyphenyl)methyl]-6-[(1,1-dimethylethyl)amino]-9H-purin-2-yl]amino]-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 867032-00-6 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-(1-methylethyl)-N2-[2-[2-(4-morpholinyl)ethoxy]-6-benzothiazolyl]-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867032-01-7 HCAPLUS

CN 9H-Purine-2,6-diamine, 8-cyclopropyl-N6-(1,1-dimethylethyl)-N2-[2-[2-(4-morpholinyl)ethoxy]-6-benzothiazolyl]-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867032-02-8 HCAPLUS

CN 9H-Purine-2,6-diamine, 8-cyclopentyl-N6-(1,1-dimethylethyl)-N2-[2-[2-(4-morpholinyl)ethoxy]-6-benzothiazolyl]-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)




RN 867032-45-9 HCAPLUS

CN Propanimidic acid, N-(4-amino-2,6-dichloro-5-pyrimidinyl)-2-methyl-, methyl ester (CA INDEX NAME)




RN 867032-46-0 HCAPLUS

CN Cyclopentanecarboximidic acid, N-(4-amino-2,6-dichloro-5-pyrimidinyl)-, methyl ester (CA INDEX NAME)




RN 867032-47-1 HCAPLUS

CN Cyclopropanecarboximidic acid, N-(4-amino-2,6-dichloro-5-pyrimidinyl)-, methyl ester (CA INDEX NAME)



RN 867033-26-9 HCAPLUS


CN 9H-Purine-2,6,8-triamine, N8-[(2,4-dimethoxyphenyl)methyl]-N6-(1,1-dimethylethyl)-N8-methyl-N2-2-naphthalenyl-9-(tetrahydro-2H-pyran-2-yl)- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)
REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

RESULTS FROM SEARCHES IN REGISTRY AND CAPLUS

=> d que stat l13
L10 STR



VAR G1=H/AK
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 15

STEREO ATTRIBUTES: NONE
L12 20 SEA FILE=REGISTRY SSS FUL L10
L13 1 SEA FILE=HCAPLUS ABB=ON L12

=> d ibib abs hitstr l13 1

L13 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2005:1123774 HCAPLUS Full-text
DOCUMENT NUMBER: 143:405752
TITLE: Preparation and use of 9H-purine-2,6-diamine
derivatives in the treatment of cancer
INVENTOR(S): Baenteli, Rolf; Chene, Patrick; Collingwood, Stephen
Paul; Furet, Pascal; Meier, Peter; Schoepfer, Joseph
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005097135	A2	20051020	WO 2005-EP3521	20050404
WO 2005097135	A3	20060216		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA,
NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL,
SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA,
ZM, ZW

10/594,412

9/5/09

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

AU 2005230388	A1	20051020	AU 2005-230388	20050404
CA 2559014	A1	20051020	CA 2005-2559014	20050404
EP 1734968	A2	20061227	EP 2005-751682	20050404
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 1946405	A	20070411	CN 2005-80012119	20050404
BR 2005009655	A	20071009	BR 2005-9655	20050404
JP 2007531721	T	20071108	JP 2007-505519	20050404
MX 2006011486	A	20070312	MX 2006-11486	20061004
KR 2007033962	A	20070327	KR 2006-720763	20061004
IN 2006CN03675	A	20070706	IN 2006-CN3675	20061005
US 20070249639	A1	20071025	US 2007-594412	20070530


PRIORITY APPLN. INFO.:

GB 2004-7723 A 20040405

WO 2005-EP3521 W 20050404

OTHER SOURCE(S): CASREACT 143:405752; MARPAT 143:405752

GI



AB The title compds. I [R2 = aryl, bicyclic aryl, heteroaryl, bicyclic heteroaryl; R6 = aryl, heteroaryl, bicyclic aryl, bicyclic heteroaryl, aliphatic moiety; R8 = H, halo, lower alkyl, lower alkenyl, cycloalkyl, COMe, NR12R13, R12, R13 = H, lower alkyl; R9 = H, lower alkyl; NR6R9 = heterocycle] were prepared For example, reacting 2-chloro-6-(cycloheptylamino)-9H-purine with 6-aminobenzothiazole gave I [R2 = benzothiazol-6-yl, R6 = cycloheptyl, R8 = R9 = H]. I are useful in treating proliferative diseases dependent on topoisomerase II.


IT 867032-72-2P 867032-74-4P 867032-75-5P
 867032-77-7P 867032-78-8P 867032-79-9P
 867032-80-2P 867032-82-4P 867032-83-5P
 867032-84-6P 867032-85-7P 867032-92-6P
 867033-12-3P 867033-13-4P 867033-14-5P
 867033-15-6P 867033-16-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of 9H-purine-2,6-diamine derivs., anticancer activity and kinase inhibition)


RN 867032-72-2 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(1,1-dimethylethyl)-8-methyl-
 (CA INDEX NAME)




RN 867032-74-4 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(1,1-dimethylethyl)-8-ethyl-
(CA INDEX NAME)




RN 867032-75-5 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-8-ethyl-N6-(2,2,2-trifluoro-1-
methylethyl)- (CA INDEX NAME)




RN 867032-77-7 HCAPLUS

CN Butanamide, 3-[[2-(6-benzothiazolylamino)-8-ethyl-9H-purin-6-yl]amino]-
(CA INDEX NAME)




RN 867032-78-8 HCAPLUS

CN Butanoic acid, 3-[[2-(6-benzothiazolylamino)-8-ethyl-9H-purin-6-yl]amino]-
, ethyl ester (CA INDEX NAME)




RN 867032-79-9 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(1,1-dimethylethyl)-8-propyl-
(CA INDEX NAME)




RN 867032-80-2 HCAPLUS

CN 9H-Purine-2,6-diamine, N2-6-benzothiazolyl-N6-(1,1-dimethylethyl)-8-(1-methylethyl)- (CA INDEX NAME)




RN 867032-82-4 HCAPLUS

CN 2H-1-Benzopyran-2-one, 6-[[6-[(1,1-dimethylethyl)amino]-8-ethyl-9H-purin-2-yl]amino]- (CA INDEX NAME)




RN 867032-83-5 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-ethyl-N2-[2-(methylthio)-6-benzothiazolyl]- (CA INDEX NAME)




RN 867032-84-6 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-ethyl-N2-[2-[2-(4-morpholinyl)ethoxy]-6-benzothiazolyl]- (CA INDEX NAME)




RN 867032-85-7 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-(1-methylethyl)-N2-[2-[2-(4-morpholinyl)ethoxy]-6-benzothiazolyl]- (CA INDEX NAME)




RN 867032-92-6 HCAPLUS

CN Ethanone, 1-[2-(6-benzothiazolylamino)-6-[(1,1-dimethylethyl)amino]-9H-purin-8-yl]- (CA INDEX NAME)




RN 867033-12-3 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-ethenyl-N2-2-naphthalenyl- (CA INDEX NAME)




RN 867033-13-4 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-N2-2-naphthalenyl-8-(2-propen-1-yl)- (CA INDEX NAME)




RN 867033-14-5 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-methyl-N2-2-naphthalenyl-
(CA INDEX NAME)




RN 867033-15-6 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-ethyl-N2-2-naphthalenyl-
(CA INDEX NAME)



RN 867033-16-7 HCAPLUS

CN 9H-Purine-2,6-diamine, N6-(1,1-dimethylethyl)-8-(2-methylpropyl)-N2-2-naphthalenyl-
(CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

SEARCH HISTORY

=> d his ful

(FILE 'HOME' ENTERED AT 13:34:32 ON 05 SEP 2009)

FILE 'HCAPLUS' ENTERED AT 13:35:09 ON 05 SEP 2009

```

E BAENTELI ROLF/AU
L1      11 SEA ABB=ON  ("BAENTELI R"/AU OR "BAENTELI ROLF"/AU)
E CHENE PATRICK/AU
L2      70 SEA ABB=ON  ("CHENE P"/AU OR "CHENE PATRICK"/AU)
E COLLINGWOOD STEPHEN PAUL/AU
L3      45 SEA ABB=ON  ("COLLINGWOOD STEPHEN P"/AU OR "COLLINGWOOD
STEPHEN PAUL"/AU)
E FURET PASCAL/AU
L4      179 SEA ABB=ON  ("FURET P"/AU OR "FURET PASCAL"/AU)
E MEIER PETER/AU
L5      63 SEA ABB=ON  "MEIER PETER"/AU
E SCHOEPFER JOSEPH/AU
L6      49 SEA ABB=ON  ("SCHOEPFER JOSEPH"/AU OR "SCHOEPFER JOSEPH G"/AU)

L7      1 SEA ABB=ON  L1 AND L2 AND L3 AND L4 AND L5 AND L6
SELECT RN L7 1

```

FILE 'REGISTRY' ENTERED AT 13:36:31 ON 05 SEP 2009

```

L8      211 SEA ABB=ON  (102503-23-1/BI OR 1042953-23-0/BI OR 1042953-41-2/
BI OR 1042953-86-5/BI OR 1089-59-4/BI OR 110-87-2/BI OR
115-80-0/BI OR 1200-27-7/BI OR 124-68-5/BI OR 13074-39-0/BI OR
130838-36-7/BI OR 13101-88-7/BI OR 13382-43-9/BI OR 142805-56-9
/BI OR 14415-44-2/BI OR 15231-91-1/BI OR 166104-20-7/BI OR
185408-97-3/BI OR 190654-89-8/BI OR 193017-26-4/BI OR 20419-68-
5/BI OR 20781-20-8/BI OR 2407-11-6/BI OR 24850-33-7/BI OR
25706-29-0/BI OR 2941-62-0/BI OR 3240-94-6/BI OR 325166-80-1/BI
OR 34803-68-4/BI OR 3531-43-9/BI OR 411235-57-9/BI OR
41796-01-4/BI OR 43083-12-1/BI OR 5111-65-9/BI OR 5303-65-1/BI
OR 533-30-2/BI OR 536-90-3/BI OR 5451-40-1/BI OR 5452-35-7/BI
OR 5452-37-9/BI OR 580-15-4/BI OR 58460-11-0/BI OR 594-39-8/BI
OR 5959-32-0/BI OR 597-64-8/BI OR 622-40-2/BI OR 6278-73-5/BI
OR 65079-19-8/BI OR 67980-77-2/BI OR 6850-65-3/BI OR 728-87-0/B
I OR 736100-88-2/BI OR 746556-17-2/BI OR 7486-35-3/BI OR
75-64-9/BI OR 7570-47-0/BI OR 765-38-8/BI OR 78-39-7/BI OR
822-98-0/BI OR 867031-80-9/BI OR 867031-81-0/BI OR 867031-82-1/
BI OR 867031-83-2/BI OR 867031-84-3/BI OR 867031-85-4/BI OR
867031-86-5/BI OR 867031-87-6/BI OR 867031-88-7/BI OR 867031-89
-8/BI OR 867031-90-1/BI OR 867031-91-2/BI OR 867031-92-3/BI OR
867031-93-4/BI OR 867031-94-5/BI OR 867031-95-6/BI OR 867031-96
-7/BI OR 867031-97-8/BI OR 867031-98-9/BI OR 867031-99-0/BI OR
867032-00-6/BI OR 867032-01-7/BI OR 867032-02-8/BI OR 867032-03
-9/BI OR 867032-04-0/BI OR 867032-05-1/BI OR 867032-07-3/BI OR
867032-08-4/BI OR 867032-09-5/BI OR 867032-10-8/BI OR 867032-11
-9/BI OR 867032-12-0/BI OR 867032-13-1/BI OR 867032-14-2/BI OR
867032-15-3/BI OR 867032-16-4/BI OR 867032-17-5/BI OR 867032-18
-6/BI OR 867032-19-7/BI OR 867032-20-0/BI OR 867032-21-1/BI OR
867032-22-2/BI OR 867032-23-3/BI OR 867032-24-4/BI OR 867032-25
-5/BI OR 867032-26-6/BI OR 867032-27-7/BI OR 867032-28-8/BI OR
867032-29-9/BI OR 867032-30-2/BI OR 867032-31-3/BI OR 867032-32
-4/BI OR 867032-33-5/BI OR 867032-34-6/BI OR 867032-35-7/BI OR
867032-36-8/BI OR 867032-37-9/BI OR 867032-38-0/BI OR 86703

```

L9 FILE 'HCAPLUS' ENTERED AT 13:36:48 ON 05 SEP 2009
1 SEA ABB=ON L7 AND L8

L10 FILE 'REGISTRY' ENTERED AT 13:37:54 ON 05 SEP 2009
STR
L11 0 SEA SSS SAM L10
L12 20 SEA SSS FUL L10

L13 FILE 'HCAPLUS' ENTERED AT 13:41:44 ON 05 SEP 2009
1 SEA ABB=ON L12

FILE HOME

FILE HCAPLUS

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 5 Sep 2009 VOL 151 ISS 11
FILE LAST UPDATED: 4 Sep 2009 (20090904/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAplus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer to NEWS 9.

FILE REGISTRY

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 4 SEP 2009 HIGHEST RN 1180743-67-2
DICTIONARY FILE UPDATES: 4 SEP 2009 HIGHEST RN 1180743-67-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>